Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

neogen corp. - NEOG

NEOG

Close Chg Chg %
11.89 -0.01 -0.04%

Open Market

11.88

-0.01 (0.04%)

Volume: 4.44M

Last Updated:

Sep 9, 2026, 2:23 PM EDT

Trade Now

Company Overview: neogen corp. - NEOG

NEOG Key Data

Open

$12.09

 Day Range

11.75 - 12.18

52 Week Range

4.90 - 12.85

 Market Cap

$2.58B

Shares Outstanding

218.11M

 Public Float

216.02M

Beta

1.76

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.04

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.63M

  

NEOG Performance

1 Week
 
 0.46%
 
1 Month
 
 3.62%
 
3 Months
 
 30.60%
 
1 Year
 
 116.09%
 
5 Years
 
 -72.01%
 

NEOG Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About neogen corp. - NEOG

Neogen Corp. engages in the provision of development, manufacture, and marketing of food and animal safety products. It operates through the Food Safety and Animal Safety segments. The Food Safety segment consists of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, drug residues, and levels of general sanitation. The Animal Safety segment includes a line of consumable products marketed to veterinarians and animal health product distributors. The company was founded on June 30, 1981 and is headquartered in Lansing, MI.

NEOG At a Glance

Neogen Corp.
620 Lesher Place
Lansing, Michigan 48912
Phone 1-517-372-9200 Revenue 870.40M
Industry Medical Specialties Net Income -7,900,000.00
Sector Health Technology Employees 2,636
Fiscal Year-end 05 / 2027
View SEC Filings

NEOG Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.241
Price to Book Ratio 0.933
Price to Cash Flow Ratio 23.45
Enterprise Value to EBITDA 24.044
Enterprise Value to Sales 2.961
Total Debt to Enterprise Value 0.315

NEOG Efficiency

Revenue/Employee 330,197.269
Income Per Employee -2,996.965
Receivables Turnover 5.929
Total Asset Turnover 0.253

NEOG Liquidity

Current Ratio 3.822
Quick Ratio 2.91
Cash Ratio 1.173

NEOG Profitability

Gross Margin 46.932
Operating Margin -1.677
Pretax Margin -1.034
Net Margin -0.908
Return on Assets -0.23
Return on Equity -0.379
Return on Total Capital -0.272
Return on Invested Capital -0.27

NEOG Capital Structure

Total Debt to Total Equity 38.798
Total Debt to Total Capital 27.953
Total Debt to Total Assets 23.926
Long-Term Debt to Equity 38.573
Long-Term Debt to Total Capital 27.791
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Neogen Corp. - NEOG

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
822.45M 924.22M 894.66M 870.40M
Sales Growth
+56.01% +12.37% -3.20% -2.71%
Cost of Goods Sold (COGS) incl D&A
416.49M 461.59M 473.29M 461.90M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
88.38M 121.23M 125.67M 121.80M
Depreciation
17.29M 26.28M 31.75M 30.00M
Amortization of Intangibles
71.08M 94.95M 93.92M 91.80M
COGS Growth
+46.58% +10.83% +2.53% -2.41%
Gross Income
405.95M 462.63M 421.38M 408.50M
Gross Income Growth
+67.05% +13.96% -8.92% -3.06%
Gross Profit Margin
+49.36% +50.06% +47.10% +46.93%
2023 2024 2025 2026 5-year trend
SG&A Expense
368.44M 385.21M 411.96M 423.10M
Research & Development
26.04M 22.48M 21.09M 18.40M
Other SG&A
342.40M 362.73M 390.87M 404.70M
SGA Growth
+99.81% +4.55% +6.94% +2.71%
Other Operating Expense
- - - -
-
Unusual Expense
(300.00K) 18.54M 1.07B 7.80M
EBIT after Unusual Expense
37.81M 58.89M (1.06B) (22.40M)
Non Operating Income/Expense
(3.90M) 2.48M (975.00K) 71.00M
Non-Operating Interest Income
- 3.17M 6.36M 3.11M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
55.96M 75.67M 69.68M 57.60M
Interest Expense Growth
- +35.23% -7.92% -17.34%
Gross Interest Expense
55.96M 75.67M 69.68M 57.60M
Interest Capitalized
- - - -
-
Pretax Income
(22.04M) (14.30M) (1.13B) (9.00M)
Pretax Income Growth
-136.61% +35.10% -7,821.08% +99.21%
Pretax Margin
-2.68% -1.55% -126.65% -1.03%
Income Tax
828.00K (4.88M) (41.07M) (1.10M)
Income Tax - Current - Domestic
10.57M 10.19M 1.61M 3.50M
Income Tax - Current - Foreign
9.49M 14.41M 14.09M 19.70M
Income Tax - Deferred - Domestic
(19.27M) (27.34M) (41.07M) (26.20M)
Income Tax - Deferred - Foreign
41.00K (2.15M) (15.69M) 1.90M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(22.87M) (9.42M) (1.09B) (7.90M)
Minority Interest Expense
- - - -
-
Net Income
(22.87M) (9.42M) (1.09B) (7.90M)
Net Income Growth
-147.34% +58.81% -11,491.59% +99.28%
Net Margin Growth
-2.78% -1.02% -122.06% -0.91%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(22.87M) (9.42M) (1.09B) (7.90M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(22.87M) (9.42M) (1.09B) (7.90M)
EPS (Basic)
-0.1211 -0.0435 -5.0349 -0.0363
EPS (Basic) Growth
-127.00% +64.08% -11,474.48% +99.28%
Basic Shares Outstanding
188.88M 216.48M 216.89M 217.50M
EPS (Diluted)
-0.1211 -0.0435 -5.0349 -0.0363
EPS (Diluted) Growth
-127.08% +64.08% -11,474.48% +99.28%
Diluted Shares Outstanding
188.88M 216.48M 216.89M 217.50M
EBITDA
125.89M 198.65M 135.09M 107.20M
EBITDA Growth
+52.94% +57.80% -32.00% -20.65%
EBITDA Margin
+15.31% +21.49% +15.10% +12.32%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 13.00
Number of Ratings 5 Current Quarters Estimate 0.093
FY Report Date 11 / 2026 Current Year's Estimate 0.31
Last Quarter’s Earnings 0.05 Median PE on CY Estimate N/A
Year Ago Earnings 0.32 Next Fiscal Year Estimate 0.41
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 2
Mean Estimate 0.09 0.07 0.31 0.41
High Estimates 0.10 0.10 0.35 0.43
Low Estimate 0.08 0.04 0.28 0.39
Coefficient of Variance 12.37 45.83 11.63 6.90

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 2
OVERWEIGHT 0 0 0
HOLD 2 2 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Neogen Corp. - NEOG

Date Name Shares Transaction Value
Aug 21, 2026 Mikhael Nassif CEO; Director 25,655 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.87 per share 304,524.85
Aug 21, 2026 John Moylan Chief Accounting Officer 29,331 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.87 per share 348,158.97
Oct 29, 2025 Amy M. Rocklin Chief Legal Officer 59,325 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 367,221.75
Oct 29, 2025 David H. Naemura Chief Financial Officer 15,504 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 29, 2025 David H. Naemura Chief Financial Officer 81,024 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 501,538.56
Oct 29, 2025 David H. Naemura Chief Financial Officer 85,285 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 527,914.15
Oct 29, 2025 Amy M. Rocklin Chief Legal Officer 57,240 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 354,315.60
Oct 29, 2025 Amy M. Rocklin Chief Legal Officer 9,474 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 28, 2025 Catherine E. Woteki Director 35,084 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 212,959.88
Oct 28, 2025 Jeffrey D. Capello Director 48,469 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 294,206.83
Oct 28, 2025 Catherine E. Woteki Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Andrea F. Wainer Director 19,769 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 119,997.83
Oct 28, 2025 Ronald D. Green Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Ronald D. Green Director 34,621 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 210,149.47
Oct 28, 2025 Raphael A. Rodriguez Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Raphael A. Rodriguez Director 36,788 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 223,303.16
Oct 28, 2025 Thierry L. Bernard Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 Thierry L. Bernard Director 19,769 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 119,997.83
Oct 28, 2025 James C. Borel Director 50,814 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 28, 2025 James C. Borel Director 112,314 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.07 per share 681,745.98

Neogen Corp. in the News